299 related articles for article (PubMed ID: 31441380)
41. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
[TBL] [Abstract][Full Text] [Related]
42. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
[TBL] [Abstract][Full Text] [Related]
43. Cardiotoxin III suppresses hepatocyte growth factor-stimulated migration and invasion of MDA-MB-231 cells.
Tsai PC; Chu CL; Chiu CC; Chang LS; Lin SR
Cell Biochem Funct; 2014 Aug; 32(6):485-95. PubMed ID: 24964901
[TBL] [Abstract][Full Text] [Related]
44. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
45. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
46. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.
Ogunwobi OO; Puszyk W; Dong HJ; Liu C
PLoS One; 2013; 8(5):e63765. PubMed ID: 23723997
[TBL] [Abstract][Full Text] [Related]
47. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
48. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y; Yeganeh M; Donates YC; Tobelaim WS; Chababi W; Mayhue M; Yoshimura A; Ramanathan S; Saucier C; Ilangumaran S
Oncogene; 2015 Nov; 34(46):5718-28. PubMed ID: 25728680
[TBL] [Abstract][Full Text] [Related]
49. Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway.
Shen Y; Chen Q; Li L
Mol Cell Probes; 2019 Jun; 45():57-64. PubMed ID: 31096000
[TBL] [Abstract][Full Text] [Related]
50. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma.
Korhan P; Erdal E; Kandemiş E; Cokaklı M; Nart D; Yılmaz F; Can A; Atabey N
PLoS One; 2014; 9(8):e105278. PubMed ID: 25148256
[TBL] [Abstract][Full Text] [Related]
51. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling.
Parr C; Ali AY
J Transl Med; 2018 Oct; 16(1):281. PubMed ID: 30314527
[TBL] [Abstract][Full Text] [Related]
52. Ganglioside GM3 promotes HGF-stimulated motility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling.
Li Y; Huang X; Zhong W; Zhang J; Ma K
Mol Cell Biochem; 2013 Oct; 382(1-2):83-92. PubMed ID: 23749170
[TBL] [Abstract][Full Text] [Related]
53. Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials.
Li Y; Huang X; Zhang Q; Ma K
Mol Med Rep; 2013 Aug; 8(2):655-61. PubMed ID: 23778885
[TBL] [Abstract][Full Text] [Related]
54. RhoA-Dependent HGF and c-Met Mediate Gas6-Induced Inhibition of Epithelial-Mesenchymal Transition, Migration, and Invasion of Lung Alveolar Epithelial Cells.
Jung J; Yang K; Kim HJ; Lee YJ; Kim M; Choi YH; Kang JL
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31590238
[TBL] [Abstract][Full Text] [Related]
55. Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma.
Jafarnejad M; Sové RJ; Danilova L; Mirando AC; Zhang Y; Yarchoan M; Tran PT; Pandey NB; Fertig EJ; Popel AS
NPJ Syst Biol Appl; 2019; 5():29. PubMed ID: 31452933
[TBL] [Abstract][Full Text] [Related]
56. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
Coxon A; Rex K; Meyer S; Sun J; Sun J; Chen Q; Radinsky R; Kendall R; Burgess TL
Mol Cancer Ther; 2009 May; 8(5):1119-25. PubMed ID: 19435874
[TBL] [Abstract][Full Text] [Related]
57. PKCε-mediated c-Met endosomal processing directs fluctuant c-Met-JNK-paxillin signaling for tumor progression of HepG2.
Hu CT; Cheng CC; Wu JR; Pan SM; Wu WS
Cell Signal; 2015 Jul; 27(7):1544-55. PubMed ID: 25778903
[TBL] [Abstract][Full Text] [Related]
58. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.
Li Y; Guessous F; DiPierro C; Zhang Y; Mudrick T; Fuller L; Johnson E; Marcinkiewicz L; Engelhardt M; Kefas B; Schiff D; Kim J; Abounader R
Mol Cancer Ther; 2009 Feb; 8(2):376-85. PubMed ID: 19190120
[TBL] [Abstract][Full Text] [Related]
59. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
60. Madecassoside suppresses proliferation and invasiveness of HGF-induced human hepatocellular carcinoma cells via PKC-cMET-ERK1/2-COX-2-PGE2 pathway.
Li Z; You K; Li J; Wang Y; Xu H; Gao B; Wang J
Int Immunopharmacol; 2016 Apr; 33():24-32. PubMed ID: 26851630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]